AAAAAA

   
Results: 1-25 | 26-50 | 51-60 |
Results: 51-60/60
Late-onset hypertrophic cardiomyopathy caused by a mutation in the cardiactroponin T gene
Authors: Elliott, PM D'Cruz, L McKenna, WJ
Citation: Pm. Elliott et al., Late-onset hypertrophic cardiomyopathy caused by a mutation in the cardiactroponin T gene, N ENG J MED, 341(24), 1999, pp. 1855-1856
Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management - Part III
Authors: Priori, SG Barhanin, J Hauer, RNW Haverkamp, W Jongsma, HJ Kleber, AG McKenna, WJ Roden, DM Rudy, Y Schwartz, K Schwartz, PJ Towbin, JA Wilde, AM
Citation: Sg. Priori et al., Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management - Part III, CIRCULATION, 99(5), 1999, pp. 674-681
Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II
Authors: Priori, SG Barhanin, J Hauer, RNW Haverkamp, W Jongsma, HJ Kleber, AG McKenna, WJ Roden, DM Rudy, Y Schwartz, K Schwartz, PJ Towbin, JA Wilde, AM
Citation: Sg. Priori et al., Genetic and molecular basis of cardiac arrhythmias: Impact on clinical management parts I and II, CIRCULATION, 99(4), 1999, pp. 518-528
Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy - A randomized, double-blind, crossover study (M-PATHY)
Authors: Maron, BJ Nishimura, RA McKenna, WJ Rakowski, H Josephson, ME Kieval, RS
Citation: Bj. Maron et al., Assessment of permanent dual-chamber pacing as a treatment for drug-refractory symptomatic patients with obstructive hypertrophic cardiomyopathy - A randomized, double-blind, crossover study (M-PATHY), CIRCULATION, 99(22), 1999, pp. 2927-2933
Evaluation of the risk of sudden death in hypertrophic cardiomyopathy.
Authors: Sadoul, N de Chillou, C Aliot, E McKenna, WJ
Citation: N. Sadoul et al., Evaluation of the risk of sudden death in hypertrophic cardiomyopathy., ARCH MAL C, 92, 1999, pp. 65-73
Continuous intravenous dobutamine is associated with an increased risk of death in patients advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST)
Authors: O'Connor, CM Gattis, WA Uretsky, BF Adams, KF McNulty, SE Grossman, SH McKenna, WJ Zannad, F Swedberg, K Gheorghiada, M Califf, RM
Citation: Cm. O'Connor et al., Continuous intravenous dobutamine is associated with an increased risk of death in patients advanced heart failure: Insights from the Flolan International Randomized Survival Trial (FIRST), AM HEART J, 138(1), 1999, pp. 78-86
The epidemiology of heart failure secondary to coronary artery disease
Authors: Goldman, JH McKenna, WJ
Citation: Jh. Goldman et Wj. Mckenna, The epidemiology of heart failure secondary to coronary artery disease, CORON ART D, 9(10), 1998, pp. 625-628
Calcium channel blockers in cardiac failure
Authors: Mahon, N McKenna, WJ
Citation: N. Mahon et Wj. Mckenna, Calcium channel blockers in cardiac failure, PROG CARD, 41(3), 1998, pp. 191-206
QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy
Authors: Yi, G Elliott, P McKenna, WJ Prasad, K Sharma, S Guo, XH Camm, AJ Malik, M
Citation: G. Yi et al., QT dispersion and risk factors for sudden cardiac death in patients with hypertrophic cardiomyopathy, AM J CARD, 82(12), 1998, pp. 1514-1519
Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction
Authors: Lorenzoni, R Gistri, R Cecchi, F Olivotto, I Chiriatti, G Elliott, P McKenna, WJ Camici, PG
Citation: R. Lorenzoni et al., Coronary vasodilator reserve is impaired in patients with hypertrophic cardiomyopathy and left ventricular dysfunction, AM HEART J, 136(6), 1998, pp. 972-981
Risultati: 1-25 | 26-50 | 51-60 |